Completed PHASE3 INTERVENTIONAL NCT00363857

A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome

A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS)

Sponsor: GlaxoSmithKline

Conditions Restless Legs Syndrome Restless Legs Syndrome (RLS)

Interventions Ropinirole

Updated 5 times since 2017 Last updated: Oct 14, 2016 Started: Aug 31, 2003 Primary completion: May 31, 2004 Completion: May 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00363857, this PHASE3 trial focuses on Restless Legs Syndrome and Restless Legs Syndrome (RLS) and remains completed. Sponsored by GlaxoSmithKline, it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alabaster, United States , Albuquerque, United States , Alexandria, United States , Atlanta, United States , Augusta, United States , Aurora, United States , Austin, United States , Berkeley, United States , Birmingham, United States , Boca Raton, United States and 37 more locations